• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by I-MAB (Amendment)

    6/30/23 4:05:14 PM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMAB alert in real time by email
    SC 13D/A 1 p23-1909sc13da.htm I-MAB
    SECURITIES AND EXCHANGE COMMISSION  
    Washington, D.C. 20549  
       
    SCHEDULE 13D/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 5)*
     

    I-MAB

    (Name of Issuer)
     

    Ordinary Shares

    (Title of Class of Securities)
     

    44975P103**

    (CUSIP Number)
     

    Richard A. Hornung

    HHLR Advisors, Ltd.

    Office #122, Windward 3 Building, Regatta Office Park

    West Bay Road, Grand Cayman

    Cayman Islands, KY1-9006

    + 345-749-8643

     

    With a copy to:

     

    Eleazer N. Klein, Esq.

    Adriana F. Schwartz, Esq.

    Schulte Roth & Zabel LLP

    919 Third Avenue

    New York, NY 10022

    (212) 756-2000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     

    June 28, 2023

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. [ ]

    (Page 1 of 6 Pages)

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    ** There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 44975P103 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on the Nasdaq Global Market under the symbol “IMAB.” Each 10 ADSs represents 23 Ordinary Shares.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 44975P103SCHEDULE 13D/APage 2 of 6 Pages

     

    1

    NAME OF REPORTING PERSON

    HHLR Advisors, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF (See Item 3)

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    15,891,211 Ordinary Shares*

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    15,891,211 Ordinary Shares*

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    15,891,211 Ordinary Shares*

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    8.3%

    14

    TYPE OF REPORTING PERSON

    IA

             

     

    * Consists of (i) 6,909,220 ADSs representing 15,891,206 ordinary shares held by funds managed by HHLR (as defined below) and (ii) 5 ordinary shares held by a fund managed by HIM (as defined below). HHLR and HIM are under common control and share certain policies, personnel and resources.

     

     

    CUSIP No. 44975P103SCHEDULE 13D/APage 3 of 6 Pages

     

    1

    NAME OF REPORTING PERSON

    Hillhouse Investment Management, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF (See Item 3)

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    15,891,211 Ordinary Shares*

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    15,891,211 Ordinary Shares*

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    15,891,211 Ordinary Shares*

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    8.3%

    14

    TYPE OF REPORTING PERSON

    IA

             

     

    * Consists of (i) 6,909,220 ADSs representing 15,891,206 ordinary shares held by funds managed by HHLR and (ii) 5 ordinary shares held by a fund managed by HIM. HHLR and HIM are under common control and share certain policies, personnel and resources.

     

      

     

    CUSIP No. 44975P103SCHEDULE 13D/APage 4 of 6 Pages

    This Amendment No. 5 (“Amendment No. 5”) amends the statement on Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on September 14, 2020, as amended by Amendment No. 1 filed on December 21, 2021, Amendment No. 2 filed on March 25, 2021, Amendment No. 3 filed on June 24, 2021, Amendment No. 4 filed on September 27, 2021 and as amended hereby (the “Schedule 13D”), with respect to the ordinary shares, par value $0.0001 per share (the “Ordinary Shares”) of I-MAB, an exempted Cayman Islands company (the “Issuer”). Capitalized terms used herein and not otherwise defined in this Amendment No. 5 have the meanings set forth in the Schedule 13D. This Amendment No. 5 amends Items 5(a)-(c) as set forth below.

     

    Item 5. Interest in Securities of the Issuer
     
    Items 5(a)-(c) of the Schedule 13D are hereby amended and restated as follows:

     

    (a) See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of Ordinary Shares and percentages of the Ordinary Shares beneficially owned by each Reporting Person.  The percentage used in this Schedule 13D is calculated based upon 191,911,402 Ordinary Shares outstanding as of March 31, 2023, as reported the Issuer's Annual Report of Foreign Issuer filed on Form 20-F with the Securities and Exchange Commission on May 1, 2023.
       
    (b) See rows (7) through (10) of the cover pages to this Schedule 13D for the number of Ordinary Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
       
    (c) Information concerning transactions in the Ordinary Shares (which were in the form of ADS) effected by the Reporting Persons in the last 60 days is set forth in Annex A hereto and is incorporated herein by reference.

     

     

    CUSIP No. 44975P103SCHEDULE 13D/APage 5 of 6 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this Schedule 13D is true, complete and correct.

     

    Date: June 30, 2023

     

      HHLR Advisors, Ltd.
       
       
     

    /s/ Audrey Woon

      Name: Audrey Woon
      Title: Chief Compliance Officer
       
       
      HILLHOUSE INVESTMENT MANAGEMENT, LTD.
       
       
     

    /s/ Audrey Woon

      Name: Audrey Woon
      Title: Chief Compliance Officer

     

     

     

     

    CUSIP No. 44975P103SCHEDULE 13D/APage 6 of 6 Pages

    Annex A

     

    Transactions in the Ordinary Shares in the Past 60 Days

     

    The following tables set forth transactions in the Ordinary Shares (which were in the form of ADS) in the past 60 days by the Reporting Persons. Except as noted below, all such transactions were effected in the open market through brokers and the price per share is net of commissions.

     

    Trade Date ADSs Purchased (Sold)* Price Per ADS ($)*
         
    06/28/2023 (45,222) 3.0313

     

    * The shares purchased or sold were in the form of ADS. The reported price is the price of each ADS purchased or sold. Each 10 ADSs represents 23 Ordinary Shares.

     

     

    Get the next $IMAB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMAB

    DatePrice TargetRatingAnalyst
    12/9/2021$96.00Buy
    Siebert Williams Shank
    11/1/2021$83.00 → $85.00Buy
    Needham
    9/1/2021$75.00 → $95.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $IMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Siebert Williams Shank initiated coverage on I-Mab with a new price target

    Siebert Williams Shank initiated coverage of I-Mab with a rating of Buy and set a new price target of $96.00

    12/9/21 8:33:47 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham reiterated coverage on I-MAB with a new price target

    Needham reiterated coverage of I-MAB with a rating of Buy and set a new price target of $85.00 from $83.00 previously

    11/1/21 4:39:06 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on I-MAB with a new price target

    HC Wainwright & Co. reiterated coverage of I-MAB with a rating of Buy and set a new price target of $95.00 from $75.00 previously

    9/1/21 6:14:32 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    SEC Filings

    View All

    SEC Form 6-K filed by I-MAB

    6-K - I-Mab (0001778016) (Filer)

    8/20/25 7:00:03 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by I-MAB

    6-K - I-Mab (0001778016) (Filer)

    8/11/25 7:06:07 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by I-MAB

    424B5 - I-Mab (0001778016) (Filer)

    8/4/25 7:30:26 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update

    Positive givastomig Phase 1b dose escalation data in combination with immunochemotherapy in patients with 1L gastric cancers presented at ESMO GI 2025 showing 83% ORR at doses selected for ongoing expansion studyTopline data from planned dose expansion study of givastomig expected in Q1 2026Strengthened balance sheet with net proceeds of approximately $61.2 million from August 2025 underwritten offering; pro-forma cash balance of approximately $226.8 million as of June 30, 2025, after giving effect to the offering; expected to fund planned operating expenses and capital expenditures through the fourth quarter of 2028 ROCKVILLE, Md., Aug. 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (I

    8/20/25 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers

    Enrollment in the planned second dose expansion cohort completed ahead of expectationsTopline results expected in Q1 2026 Positive Phase 1b dose escalation data presented at ESMO GI on July 2nd ROCKVILLE, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that enrollment in the planned Phase 1b dose expansion cohorts evaluating givastomig, a bispecific Claudin 18.2 x 4-1BB antibody, in combination with nivolumab and mFOLFOX6, has been completed ahead of expectations. The Phase 1b study (NCT04900818) is evaluating the

    8/11/25 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Everest Medicines Expands Strategic Investment in I-MAB

    - Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares already held by Everest, the pro forma ownership will be 16.1%. - I-Mab's Claudin 18.2 x 4-1BB bispecific antibody, givastomig, demonstrated an impressive overall response rate (ORR) of 83% in combination with immunotherapy in a Phase 1b trial of first line gastric cancers. - I-Mab's differentiated 4-1BB receptor targeting platform and bispecific antibody pipeline are highly complementary with the Company's existing mRNA cancer vaccines and in vivo CAR-T platform. - Complementary and synergistic clinical development and business development platforms, especially I-

    8/1/25 8:56:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    Financials

    Live finance-specific insights

    View All

    I-Mab to Release Q3 2024 Financial Results on November 14, 2024

    ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time. The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year fin

    10/31/24 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

    Completed divestiture of China operationsUliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody)Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies (CLDN18.2 X 4-1BB bispecific)Ragistomig presentation at ASCO 2024 highlights encouraging early data (PD-L1 X 4-1BB bispecific)Well-positioned for pipeline advancement with $207.5 million in cash and cash equivalents, and short-term investments as of June 30, 2024, and cash runway expected into 2027I-Mab will hold a conference call and webcast today, August 28th, at 8:00 AM ETROCKVILLE, Md., Aug. 28, 2024 /PRNews

    8/28/24 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab to Release 1H 2024 Financial Results on August 28, 2024

    Conference call to discuss financial results and recent business highlights to take place on Wednesday, August 28, 2024, at 8:00 AM ET ROCKVILLE, Md., Aug. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to host a conference call and webcast on Wednesday, August 28, 2024, 8:00 AM ET to discuss financial results, pipeline progress and recent business highlights for the half year ended June 30, 2024.

    8/14/24 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    Leadership Updates

    Live Leadership Updates

    View All

    I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

    Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025Enrollment completed ahead of schedule in the first givastomig Phase 1b dose expansion cohort; momentum continues in the second expansion cohortStrong financial position supported by $173.4 million of cash and cash equivalents, and short-term investments as of December 31, 2024; provides runway into 2027, through expected clinical readouts for givastomig ROCKVILLE, Md., April 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology

    4/3/25 4:01:00 PM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

    Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritizationThe Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, and data is expected in the early second half of 2025; a 40-patient dose expansion study is now underway with data expected in early 2026Cash balance of $184.4 million (as of September 30, 2024), expected to support operations into 2027, complemented by a strengthened U.S.-based leadership team and streamlined operating modelROCKVILLE, MD, Jan. 6, 2025 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based,

    1/6/25 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Reports Third Quarter 2024 Results

    Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy dataOn track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024Estimated cash runway into 2027, based on $184.4 million in cash and cash equivalents, and short-term investments as of September 30, 2024ROCKVILLE, Md., Nov. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the three and nine months ended

    11/14/24 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by I-MAB (Amendment)

    SC 13G/A - I-Mab (0001778016) (Subject)

    2/13/24 11:26:50 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by I-MAB (Amendment)

    SC 13G/A - I-Mab (0001778016) (Subject)

    2/9/24 4:01:20 PM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by I-MAB

    SC 13D - I-Mab (0001778016) (Subject)

    12/1/23 2:41:06 PM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care